![]() |
![]() |
![]() |
About half of the use of anticancer chemotherapy drugs is for “off-label” indications – uses not listed on the FDA-approved label. Public and private payers typically cover off-label indications for anticancer drugs if they are listed in the compendia or supported in peer-reviewed medical literature. Coverage and payment for off-label uses of anticancer drugs has contributed to the widespread availability of these critical therapies. Both public and private payers are examining their choices of compendia for determining medically-accepted uses of anticancer drugs. CMS recently established an annual compendia review process. CMS will accept requests for changes to its approved list of compendia, and will publish final decisions by July 15 after collecting public comments. CMS’ decisions are poised to have an immediate impact on Medicare coverage. Concurrently, private payers are endorsing specific compendia for use in making coverage decisions for chemotherapy drugs. Join Avalere Health for a 90-minute interactive audio conference that will highlight:
*For information, please call Tom Moreno at 202.207.3471 or email tmoreno@avalerehealth.net. Cancellation Policy: To receive a refund, notice is required at least seven business days prior to the audio conference. With proper notice, fees are refunded minus a $40 service fee. No refunds are given for cancellations received with less than seven days notice. Avalere Health reserves the right to cancel or reschedule an audio conference due to unforeseen circumstances. |
||||||||||||||||
| © 2007 - Avalere Health LLC | Privacy Policy |